The estimated Net Worth of Christina K. Isacson is at least $2.65 Milion dollars as of 24 December 2019. Christina Isacson owns over 4,463 units of Magenta Therapeutics Inc stock worth over $58,650 and over the last 6 years he sold MGTA stock worth over $316,640. In addition, he makes $2,277,560 as Chief Business Officer at Magenta Therapeutics Inc.
Sign up
Christina Isacson MGTA stock SEC Form 4 insiders trading
Christina has made over 3 trades of the Magenta Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,463 units of MGTA stock worth $71,453 on 24 December 2019.
The largest trade he's ever made was selling 9,867 units of Magenta Therapeutics Inc stock on 23 December 2019 worth over $158,168. On average, Christina trades about 3,291 units every 31 days since 2018. As of 24 December 2019 he still owns at least 83,786 units of Magenta Therapeutics Inc stock.
You can see the complete history of Christina Isacson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christina Isacson biography
Dr. Christina K. Isacson Ph.D. serves as Chief Business Officer of the Company. serves as Chief Business Officer of the Company. Dr. Isacson has over 15 years of experience in corporate development in biotechnology companies and in company creation. Dr. Isacson is responsible for Magenta’s business development, alliance management, portfolio management and commercial strategy. Prior to joining Magenta, Dr. Isacson was Principal at Third Rock Ventures, LLC from September 2013 to July 2016 where she led the partner development team and focused on new company formation, including the formation of Magenta. While at Third Rock Ventures, she was part of the founding management team for Decibel Therapeutics Inc. and Interim Head of Business Development for Edimer Pharmaceuticals Inc. Prior to joining Third Rock Ventures, LLC, Christina was a senior member of the corporate development team at Ironwood Pharmaceuticals, Inc. (“Ironwood”), from July 2007 to September 2013, where she led the business and commercial roles on several development teams, and contributed to the growth of the pipeline through the establishment and management of the company’s in-licensing efforts. Prior to Ironwood, she formed several early-stage companies while part of the Technology Development Fund at Boston University and during her time at Accelerator Corporation in Seattle.
What is the salary of Christina Isacson?
As the Chief Business Officer of Magenta Therapeutics Inc, the total compensation of Christina Isacson at Magenta Therapeutics Inc is $2,277,560. There are no executives at Magenta Therapeutics Inc getting paid more.
How old is Christina Isacson?
Christina Isacson is 41, he's been the Chief Business Officer of Magenta Therapeutics Inc since 2017. There are 19 older and 1 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.
What's Christina Isacson's mailing address?
Christina's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Insiders trading at Magenta Therapeutics Inc
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... oraz Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.
What does Magenta Therapeutics Inc do?
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
What does Magenta Therapeutics Inc's logo look like?
Complete history of Christina Isacson stock trades at Magenta Therapeutics Inc
Magenta Therapeutics Inc executives and stock owners
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christina Isacson,
Chief Business Officer -
Jason Gardner,
President, Chief Executive Officer, Co-Founder, Director -
John Davis,
Chief Medical Officer, Head of Research and Development -
Dr. Jason Gardner Ph.D.,
Co-Founder, CEO, Pres & Director -
Stephen F. Mahoney J.D., MBA,
Chief Financial & Operating Officer and Treasurer -
Anne McGeorge,
Independent Director -
David Scadden,
Independent Director -
Michael Bonney,
Independent Chairman of the Board -
Alexis Borisy,
Independent Director -
Jeffrey Albers,
Independent Director -
Thomas Daniel,
Independent Director -
Bruce Booth,
Independent Director -
Blake Byers,
Independent Director -
Amy Ronneberg,
Independent Director -
Steve Mahoney,
Chief Financial and Operating Officer -
Manisha Pai,
Vice President - Communications and Investor Relations -
Zoran Zdraveski,
Secretary and Chief Legal Officer -
Li Malmberg,
Senior Vice President - Head of Manufacturing -
Kristen Stants,
Chief People Officer -
Cindy Driscoll,
Vice President - Finance -
Dr. Jan Pinkas Ph.D.,
Sr. VP & Head of Translational Sciences -
Catherine Monaghan,
Head of Clinical Devel. Operations -
Kristen Stants,
Chief People Officer -
Lyndsey Scull,
Director of Corp. Communications -
Thomas W. Beetham,
Chief Legal Officer -
Jim Haney,
Sr. Director of Investor Relations -
Dr. Lisa M. Olson Ph.D.,
Head of Research & Chief Scientific Officer -
David Wayne Nichols,
Chief Technical Officer -
Lisa Olson,
See Remarks -
Caren Deardorf,
Chief Commercial Officer -
Venture Fund X, L.P.Atlas V...,
-
Rock Ventures Iv, L.P.Third...,
-
2016 Gp, L.L.C.Gv 2016 Gp, ...,
-
Jason Ryan,
See Remarks -
Venture Fund X, L.P. Atlas,
10% owner -
Stephen F. Mahoney,
See Remarks -
Michael P. Cooke,
Chief Scientific Officer -
Thomas W. Beetham,
See Remarks -
Jeffrey Humphrey,
Chief Medical Officer -
Alison Frances Lawton,
Director -
David Wayne Nichols,
Chief Technical Officer -
Michael Vasconcelles,
Director